Author:
Seyfried Thomas N.,Rockwell Hannah E.,Heinecke Karie A.,Martin Douglas R.,Sena-Esteves Miguel
Reference84 articles.
1. Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, et al. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis. 2004;16(3):506–15.
2. Arthur JR, Lee JP, Snyder EY, Seyfried TN. Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice. Neurochem Res. 2012;37(6):1335–43.
3. Arthur JR, Wilson MW, Larsen SD, Rockwell HE, Shayman JA, Seyfried TN. Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochem Res. 2013;38(4):866–75. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t.
4. Badie B, Schartner JM, Hagar AR, Prabakaran S, Peebles TR, Bartley B, et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin Cancer Res. 2003;9(2):872–7.
5. Baek RC, Kasperzyk JL, Platt FM, Seyfried TN. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. J Neurochem. 2004;90 Suppl 1:89.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献